From 100PercentFedUp - READ ORIGINAL
Some media, including videos, may only be available to view at the original.
The European Union’s (EU) European Commission announced the marketing authorization for AstraZeneca’s COVID-19 shot, upon the company’s request, has been withdrawn.
The decision was implemented on March 27, 2024, with the marketing authorization withdrawal going into effect on May 7, 2024.
“Withdrawing, at the holder’s request, the marketing authorisation granted by Decision C(2021) 698(final) for “Vaxzevria – COVID-19 Vaccine (ChAdOx1-S [recombinant])”, a medicinal product for human use,” the European Commission stated.
The European Commission announced:
Having regard to the application submitted by AstraZeneca AB on 5 March 2024 with a view to the withdrawal of the marketing authorisation for the medicinal product “Vaxzevria – COVID-19 Vaccine (ChAdOx1-S [recombinant])”,
Whereas:
(1) The placing on the market of the medicinal product “Vaxzevria – COVID-19 Vaccine (ChAdOx1-S [recombinant])”, which is entered in the Union Register of Medicinal Products under the number EU/1/21/1529 was authorised by Commission Decision C(2021) 698(final) of 29 January 2021.
(2) Following the holder’s request, that authorisation should be withdrawn,
HAS ADOPTED THIS DECISION:
Article 1
At the holder’s request, the marketing authorisation granted by Decision C(2021) 698(final) of 29 January 2021 for the medicinal product “Vaxzevria – COVID-19 Vaccine (ChAdOx1-S [recombinant])” is withdrawn.
Article 2
The withdrawal referred to in Article 1 shall be applicable with effect from 7 May 2024.
Article 3
This Decision is addressed to AstraZeneca AB, 151 85 Södertälje, Sverige.
Done at Brussels, 27.3.2024
European Union Withdraws
AstraZeneca COVID-19
Authorisation after company’s request, effective 5/7/24 pic.twitter.com/7AVTEfGcIS— Kelly DNP
Functional/Integrative Med (@kacdnp91) May 7, 2024
Read the full document below:
“Quietly and secretly: EU stops approval for #AstraZeneca’s #corona ‘vaccine,’” German European Parliament member Christine Anderson said.
“The billions have been earned, the scam has been driven through the streets and #BigPharma is finally satiated. Today it becomes known that the @EU_Commission quietly revoked the approval of #Vaxzevria already 5 weeks ago,” she added.
Quietly and secretly: EU stops approval for #AstraZeneca‘s #corona “vaccine”
The billions have been earned, the scam has been driven through the streets and #BigPharma is finally satiated. Today it becomes known that the @EU_Commission quietly revoked the… pic.twitter.com/nxPqFn3kCe
— Christine Anderson (@AndersonAfDMdEP) May 6, 2024
The marketing authorization withdrawal of AstraZeneca’s COVID-19 shot follows revelations that the company acknowledged in court documents its shot can cause blood clotting.
COVID-19 Jab Manufacturer Admits For First Time Shot CAN Cause Blood Clotting
"AstraZeneca faces up to £255million compensation bill for 'defective' Covid vaccine after pharma titan admitted it DOES cause ultra-rare blood clot side effect," Daily Mail stated.
AstraZeneca faces up to £255million compensation bill for 'defective' Covid vaccine after pharma titan admitted it DOES cause ultra-rare blood clot side effect - as wife of victim says 'we're not going to give up' https://t.co/FFlHBVuPh2 pic.twitter.com/fFP8CBqMSR
— Daily Mail Online (@MailOnline) April 29, 2024
Per Daily Mail:
More than £250million could be given to victims allegedly harmed by AstraZeneca's Covid vaccine, MailOnline can reveal today.
Fifty-one families are pursuing legal action against the pharmaceutical titan, arguing the 'defective' jab was to blame for their injuries and deaths of loved ones.
Lawyers involved in the huge legal battle think some victims could be in line for pay-outs worth up to £5million.
As such, the total compensation bill – which would be footed by taxpayers because of a deal AstraZeneca struck with the Government before the roll-out commenced – could theoretically reach £255m, if judges were to rule the vaccine was to blame for all of the injuries and deaths involved in the class action.
However, claims have yet to be fully quantified and some cases could eclipse or fall much short of the estimated £5million.
Some might not be proven to be down to the vaccine, which was given to millions of Britons. Deadly side effects were extraordinarily rare.
The revelation at the potential compensation bill comes after AstraZeneca admitted – for the first time – that its vaccine could cause a blood clotting syndrome linked to some of the lawsuits.
Cambridge-based AstraZeneca, which is contesting the legal battle, acknowledged in a legal document submitted to the High Court in February that its vaccine 'can, in very rare cases, cause TTS'.
TTS is short for thrombosis with thrombocytopenia syndrome – a medical condition where a person suffers blood clots along with a low platelet count. Platelets typically help the blood to clot.
AstraZeneca's admission could lead to pay-outs on a case-by-case basis.
